Temozolomide wafer - Medisun Precision Medicine

Drug Profile

Temozolomide wafer - Medisun Precision Medicine

Alternative Names: ACX-31 - Medisun Precision Medicine; ACX-31 wafer - Medisun Precision Medicine

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Accelerating Combination Therapies
  • Developer Accelerating Combination Therapies; DelMar Pharmaceuticals; Medisun Precision Medicine
  • Class 2 ring heterocyclic compounds; Amides; Epoxy compounds; Ethylene glycols; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer
  • Research Solid tumours

Most Recent Events

  • 10 Jan 2017 Accurexa files for a new patent application related to the combination therapy of a PARP inhibitor and ACX 31
  • 07 Sep 2016 DelMar and Accurexa agree to co-develop ACX 31 alongwith dianhydrogalactitol for Cancer
  • 07 Sep 2016 Early research in Solid tumours in USA (Intracerebral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top